[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Central South University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":577},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,23,0,[8,52,80,107,135,161,191,210,229,248,269,294,317,341,368,392,419,440,464,489,510,529,554],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100642718","transcranial-alternating-current-stimulation-to-enhance-mindfulness-therapy-in-generalized-anxiety-disorder-100642718",false,"NCT07648797","Transcranial Alternating Current Stimulation to Enhance Mindfulness Therapy in Generalized Anxiety Disorder","Effects and Mechanisms of Individualized Alpha-Frequency Transcranial Alternating Current Stimulation as an Augmentation Strategy for Mindfulness Therapy in Patients With Generalized Anxiety Disorder","Inclusion Criteria:\n\n* Outpatients or inpatients of The Second Xiangya Hospital of Central South University.\n* Diagnosis of generalized anxiety disorder as the primary diagnosis according to the International Classification of Diseases 11th Revision (ICD-11) diagnostic criteria, confirmed by two experienced psychiatrists.\n* Hamilton Anxiety Rating Scale (HAMA) total score of 14 or higher.\n* Aged 18 to 60 years, inclusive.\n* Right-handed.\n* Junior high school education or above, with sufficient ability to understand the study procedures, complete informed consent, clinical scales, and cognitive assessments.\n* Currently not using anxiolytic or antidepressant medications, or receiving a stable medication regimen for at least 1 month before enrollment, with no planned changes in the medication regimen during the 2-week treatment period unless clinically necessary.\n* Voluntarily agrees to participate in the study, signs the informed consent form, and is able to comply with study visits, treatment procedures, laboratory examinations, and other study requirements.\n\nExclusion Criteria:\n\n* Presence of psychotic symptoms.\n* Meeting ICD-11 diagnostic criteria for schizophrenia or other primary psychotic disorders, bipolar or related disorders, current depressive episode, dysthymic disorder, or post-traumatic stress disorder currently or within the past year.\n* Organic brain disease or severe physical illness, including but not limited to thyroid disease, systemic lupus erythematosus, diabetes, severe pulmonary, hepatic, or renal impairment, infection, or major trauma.\n* Clinically significant uncorrectable sensory impairment, such as hearing impairment that prevents effective communication.\n* Pregnancy or lactation.\n* Contraindications to transcranial electrical stimulation or related procedures, including metal implants in the body, intracranial hypertension, skull defects, brain tumor, severe heart disease, unstable vital signs due to serious physical illness, acute cerebrovascular disease, or a history of adverse reactions to electrical stimulation.\n* Any other condition that, in the investigator's judgment, makes the participant unsuitable for this study.","ALL","18 Years","60 Years",{"count":20,"type":21},99,"ESTIMATED","INTERVENTIONAL",[24],"NA","This randomized, double-blind, sham-controlled clinical trial will evaluate whether individualized alpha-frequency transcranial alternating current stimulation (tACS) can enhance the effects of mindfulness therapy in adults with generalized anxiety disorder. A total of 99 participants will be randomly assigned to one of three groups: synchronous tACS combined with mindfulness therapy, desynchronous tACS combined with mindfulness therapy, or sham tACS combined with mindfulness therapy.\n\nAll participants will receive a standardized mindfulness therapy program. The study will compare changes in anxiety symptoms, worry, mindfulness, attention control, cognitive performance, and neurophysiological measures across the three groups. Assessments will be conducted from baseline through follow-up visits to examine both clinical effects and possible neural mechanisms.",[27],"Generalized Anxiety Disorder (GAD)",[29,30,31,32,33,34,35,36,37,38],"Transcranial Alternating Current Stimulation","tACS","Mindfulness Therapy","Mindfulness Meditation","Individualized Alpha Frequency","Frontoparietal Network","Dorsolateral Prefrontal Cortex","Inferior Parietal Lobule","Worry","Executive Attention","NOT_YET_RECRUITING","2026-06-12",{"date":42,"type":43},"2026-06-16","ACTUAL",{"date":45,"type":21},"2026-06-01",{"date":47,"type":21},"2028-06-01",{"name":49,"class":50},"Central South University","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":62,"briefSummary":63,"conditions":64,"keywords":65,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":4},"100642913","mri-guided-accelerated-ctbs-for-generalized-anxiety-disorder-100642913","NCT07640945","MRI-Guided Accelerated cTBS for Generalized Anxiety Disorder","Efficacy and Neural Mechanisms of MRI-Guided Accelerated Continuous Theta Burst Stimulation Targeting the Inferior Parietal Lobule in Generalized Anxiety Disorder: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Outpatients or inpatients at the Second Xiangya Hospital who are confirmed by two experienced psychiatrists to meet the International Classification of Diseases 11th Revision (ICD-11) diagnostic criteria for generalized anxiety disorder.\n* Aged 18 to 65 years, regardless of gender.\n* Right-handed.\n* Junior high school education or above, with the ability to provide informed consent and complete cognitive assessments.\n* Able to receive anti-anxiety treatment during the follow-up period according to the instructions of outpatient or inpatient physicians.\n* Hamilton Anxiety Rating Scale (HAMA) score ≥14 and Patient Health Questionnaire-15 (PHQ-15) score ≥5.\n\nExclusion Criteria:\n\n* Presence of psychotic symptoms.\n* Diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, current psychiatric symptoms, or post-traumatic stress disorder based on SCID-5 assessment, either currently or within the past year.\n* Organic brain disease or severe somatic diseases, such as thyroid disease, lupus, diabetes, lung disease, liver disease, kidney disease, infection, or major trauma.\n* Intracranial implants.\n* Clinically significant sensory impairments that cannot be corrected, such as color blindness or hearing impairment.\n* Pregnant or breastfeeding women.\n* Positive urine drug screen.\n* Abnormal thyroid function tests.\n* Personal history of epilepsy or family history of epilepsy.\n* Receipt of physical therapy within the past six months, such as repetitive transcranial magnetic stimulation or electroconvulsive therapy.\n* Suspected or confirmed history of alcohol or drug dependence.\n* Use of anticoagulants, such as heparin or warfarin, corticosteroids, or thyroid disease treatments within the past three months.\n* Current use of psychoactive medications.\n* Receipt of neurocognitive assessments similar to those used in this study within the past 12 months.","65 Years",{"count":61,"type":21},75,[24],"Generalized Anxiety Disorder (GAD) is a common psychiatric disorder associated with persistent anxiety, functional impairment, and incomplete response to existing treatments. Although transcranial magnetic stimulation (TMS) has shown therapeutic potential in anxiety disorders, conventional treatment schedules often require several weeks and may not provide sufficiently rapid symptom relief. This study aims to evaluate the efficacy and safety of precision-targeted accelerated continuous theta-burst stimulation (cTBS) guided by individualized functional connectivity between the intraparietal sulcus (IPS) and the amygdala in patients with GAD.",[27],[27,66,67,68,69,70,71],"transcranial magnetic stimulation","Single-center","Randomized Controlled Trial","Non-invasive brain stimulation","Neuromodulation","theta burst stimulation","2026-06-09",{"date":74,"type":43},"2026-06-11",{"date":76,"type":21},"2026-06",{"date":78,"type":21},"2027-02",{"name":49,"class":50},{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":90,"briefSummary":91,"conditions":92,"keywords":95,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":51},"100641976","tis-for-improving-cognitive-impairment-in-schizophrenia-100641976","NCT07647380","TIS for Improving Cognitive Impairment in Schizophrenia","Efficacy and Safety of Time Interference Stimulation on Cognitive Impairment in Patients With Schizophrenia","Inclusion Criteria:\n\n* Age 18-50 years old;\n* meet the Diagnostic and Statistical Manual of Mental Disorders, Fifth edition (DSM-5) diagnostic criteria;\n* the diagnosis of schizophrenia is confirmed by the Structured Clinical Interview for DSM-5 (SCID-5);\n* the disease duration does not exceed 8 years;\n* 1-2 antipsychotic drugs are taken, and the treatment dose of antipsychotic drugs was stable for at least 1 week before enrollment. Mood stabilizers, antidepressants, and excessive benzodiazepines (lorazepam when 2 doses exceeded 2 mg\u002Fd) are not allowed;\n* The type of antipsychotic drugs remains unchanged during treatment, and the dose is adjusted by no more than 25%;\n* Impaired functioning in daily activities;\n* The Global Deficit Score (GDS) for the MATRICS Consensus Cognitive Battery (MCCB) reaches 0.5 or above;\n* Agree to participate in this study and provide written informed consent\n\nExclusion Criteria:\n\n* Presence of other psychiatric comorbidities, intellectual disability, obvious mood symptoms, or substance use disorders (other than caffeine and\u002For tobacco);\n* with clear drug-induced extrapyramidal reaction;\n* A history of seizures, meningitis, or encephalitis;\n* with contraindications to transcranial electrical stimulation;\n* History of intracranial tumors or surgery;\n* history of severe head trauma;\n* have received other regimens of electrical or magnetic therapy in 1 month before enrollment.","50 Years",{"count":89,"type":21},50,[24],"This study aims to evaluate the efficacy, safety, and underlying neural mechanisms of TIS targeting the hippocampus in ameliorating cognitive impairment associated with schizophrenia (CIAS). Researchers will compare active TIS to a sham control to see if TIS works to treat CIAS. Participants will receive TIS twice a day for 2 weeks. Their clinical data, including the baseline clinical symptom scale score, cognitive function, E\u002FI imbalance index recorded by EEG, and MRI data, will be collected at baseline, at the end of the 2-week intervention, and 4 weeks after the intervention.",[93,94],"Schizophrenia Disorder","Cognitive Impairments",[96,97,98,99],"schizophrenia","cognitive impairments","temporal interference stimulation","excitatory-inhibitory imbalance",{"date":101,"type":43},"2026-06-15",{"date":103,"type":21},"2026-05-30",{"date":105,"type":21},"2026-12-30",{"name":49,"class":50},{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":16,"minAge":114,"maxAge":17,"enrollmentInfo":115,"targetDuration":4,"studyType":22,"phases":117,"briefSummary":119,"conditions":120,"keywords":125,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":51},"100639827","phase-2-akk-study-in-improving-obesity-and-metabolic-status-in-children-and-adolescents-100639827","NCT07593170","AKK Study in Improving Obesity and Metabolic Status in Children and Adolescents","A Randomized, Double-blind, Placebo-controlled Study of Akkermansia Muciniphila AKK PROBIO in Improving Obesity and Metabolic Abnormalities in Children and Adolescents Aged 7-18 Years","Inclusion Criteria:\n\n* Age range: 7 years old to 18 years old (inclusive of boundary values), gender not restricted.\n* Primary obesity: According to the WS\u002FT 586-2018 standard issued by the National Health Commission of China, or the internationally recognized CDC\u002FWHO standard, diagnosed as obesity (if BMI ≥ the 95th percentile of children of the same age and gender).\n* The subjects and their legal guardians understand the research content, voluntarily participate and sign the written informed consent form (for guardians), and the informed consent form (for children aged 8 years and above).\n* Able to comply with the research protocol, complete all visits and sample collection.\n\nExclusion Criteria:\n\n* Have a definite endocrine disorder causing obesity (such as Cushing's syndrome, hypothyroidism), a genetic syndrome (such as Prader-Willi syndrome), or other known organic diseases.\n* Have a severe primary disease of the liver, kidney, cardiovascular system, respiratory system or hematopoietic system, etc.\n* Have used antibiotics, probiotics, prebiotics or synbiotic products within 3 months prior to screening.\n* Have a history of systemic use of glucocorticoids or other drugs that may affect weight and metabolism (such as metformin, systemic glucocorticoids, diuretics, etc.) within 1 month prior to screening.\n* Subjects are allergic to any component of the study product (AKK probiotic capsules or placebo).\n* Subjects are participating in other clinical trials.\n* Have a history of severe gastrointestinal diseases, such as inflammatory bowel disease (IBD).\n* Other conditions as determined by the researcher to be unsuitable for participation in this study.","7 Years",{"count":116,"type":21},100,[118],"PHASE2","The problem of obesity among children and adolescents is becoming increasingly serious and may affect their health in adulthood. Researches have found that a type of probiotic in the intestinal tract - \"Akkermansia muciniphila\" (referred to as AKK), may help regulate metabolism and weight. Although it has shown effects in adults, its safety and efficacy in children and adolescents still need further verification.\n\nThis study aims to evaluate the effects of supplementing Akkermansia Muciniphila AKK PROBIO on weight, metabolic health and intestinal flora of obese children and adolescents aged 7 to 18.",[121,122,123,124],"Obesity","Obese Adolescents","Obese Children and Adolescents","Akkermansia Muciniphila",[126,127],"obesity","Akkermansia muciniphila",{"date":129,"type":43},"2026-06-03",{"date":131,"type":21},"2026-06-06",{"date":133,"type":21},"2027-02-12",{"name":49,"class":50},{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":59,"enrollmentInfo":142,"targetDuration":4,"studyType":22,"phases":144,"briefSummary":146,"conditions":147,"keywords":149,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":159,"locationsCount":160},"100596414","phase-3-metformin-alleviates-abnormal-glucose-metabolism-induced-by-statins-in-schizophrenia-patients-100596414","NCT07045142","Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients","Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients: A Randomized, Double-Blind, Placebo-Controlled Multicenter Clinical Study","Inclusion criteria:\n\n1. Aged between 18 and 65 years, regardless of gender, and meets the diagnostic criteria for schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5);\n2. Symptoms and medication regimen stable for more than 3 months, with the allowance of up to two antipsychotic medications in combination (concurrent use of antidepressants, anxiolytics, and mood stabilizers is permitted);\n3. Temporary use of benzodiazepines is allowed;\n4. Meets at least one of the following conditions: fasting total cholesterol (TC) ≥ 5.2 mmol\u002FL; fasting triglycerides (TG) ≥ 1.7 mmol\u002FL; fasting low-density lipoprotein cholesterol (LDL-C) ≥ 3.4 mmol\u002FL;\n5. Two fasting blood glucose (FPG) tests must be \\\u003C 6.1 mmol\u002FL (with an interval of 1-4 weeks);\n6. It is anticipated that there will be no issues related to relocation, transportation difficulties, or access to medical care throughout the study;\n7. Informed consent must be obtained from the patient and their guardian, and a consent form must be signed.\n\nExclusion criteria:\n\n1. Patients with a prior diagnosis of diabetes or complications such as diabetic ketoacidosis;\n2. Patients with liver or kidney dysfunction, indicated by aspartate aminotransferase (AST), alanine aminotransferase (ALT), or gamma-glutamyl transferase (GGT) levels exceeding twice the normal limits, and\u002For creatinine levels exceeding 1.2 times the upper limit of the reference range or greater than 2 mg\u002FdL, or deemed by the investigator to have liver and\u002For kidney impairment that warrants exclusion from the study;\n3. Patients with severe gastrointestinal, respiratory, endocrine, hematologic diseases, or metabolic absorption disorders: including but not limited to poorly controlled diabetes, severe acute systemic infections or immunological diseases, ischemic heart disease, cerebrovascular accidents within the past year, history of prolonged QT interval, active hepatitis B virus, chronic active hepatitis C, and malabsorption syndromes;\n4. Clinically significant abnormal ECG findings at screening that the investigator deems unsuitable for inclusion, such as male QTc interval \\> 470 ms, female QTc interval \\> 480 ms;\n5. Pregnant or nursing women.",{"count":143,"type":21},400,[145],"PHASE3","Schizophrenia is a severe mental illness associated with significant morbidity and disability. Patients often experience metabolic side effects from antipsychotic medications, including weight gain and dyslipidemia. Statins, commonly used to manage dyslipidemia, can lower cholesterol levels but may increase the risk of new-onset diabetes.\n\nThis study aims to investigate how atorvastatin affects glucose metabolism in schizophrenia patients and assess whether metformin can help improve these metabolic issues. The investigators will include 200 patients with dyslipidemia from the Second Xiangya Hospital and other sites, randomly assigning them to receive either atorvastatin with metformin or atorvastatin with placebo over six months.\n\nKey goals include evaluating the impact of atorvastatin on insulin resistance and blood glucose levels and determining the effectiveness of metformin in mitigating glucose metabolism abnormalities while managing lipid levels.\n\nUnderstanding these interactions will help improve treatment strategies for schizophrenia patients, potentially lowering their risk of cardiovascular diseases and diabetes and enhancing overall health outcomes.",[148],"Schizophrenia",[148,150,151,152],"Dyslipidemia","Metformin","Statin","RECRUITING",{"date":155,"type":43},"2026-06-02",{"date":157,"type":43},"2025-07-01",{"date":47,"type":21},{"name":49,"class":50},8,{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":168,"sex":16,"minAge":169,"maxAge":170,"enrollmentInfo":171,"targetDuration":4,"studyType":22,"phases":173,"briefSummary":174,"conditions":175,"keywords":177,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":51},"100638329","school-and-family-based-obesity-prevention-in-pakistani-primary-school-children-100638329","NCT07616232","School and Family-Based Obesity Prevention in Pakistani Primary School Children","School and Family-Based Multifaceted Intervention Program for Preventing Obesity in Primary School Children in Pakistan: A Cluster Randomized Trial","Inclusion Criteria:\n\n* Children aged 6-12 years enrolled in grades 3, 4, or 5 of selected primary schools in Lahore, Sahiwal, or Bahawalnagar, Pakistan\n* Written informed consent provided by parent or primary caregiver\n* Child assent obtained\n* Children without any medical conditions that prevent participation in physical activities\n\nExclusion Criteria:\n\n* Medical history of heart disease, hypertension, diabetes, tuberculosis, asthma, hepatitis, or nephritis\n* Obesity caused by endocrine diseases or side effects of drugs\n* Abnormal physical development (e.g., dwarfism, gigantism)\n* Physical deformity (e.g., severe scoliosis, pectus carinatum, limp, obvious O-leg or X-leg)\n* Inability to participate in school sport activities\n* Weight loss by vomiting or taking drugs during the past three months\n* Participation in another obesity prevention or treatment program\n* For schools: planned relocation or cancellation within the next two years",true,"6 Years","12 Years",{"count":172,"type":21},2340,[24],"Childhood obesity is increasing rapidly in Pakistan, but there are no large, high-quality studies testing ways to prevent it in schools. This study aims to find out if a 9-month program involving health education, daily physical activity, parent workshops, and regular feedback via WhatsApp or SMS can reduce the number of primary school children who are overweight or obese.\n\nThe study is a cluster randomized controlled trial. A total of 26 primary schools in three cities of Punjab (Lahore, Sahiwal, Bahawalnagar) will be randomly assigned to either the intervention group (13 schools) or the control group (13 schools). Children in grades 3, 4, and 5 (aged 6-12 years) will take part.\n\nIn the intervention schools, children will receive 18 health education sessions, daily 45 minutes of physical activity, and monthly weight and height checks. Parents will attend three workshops and receive weekly messages and monthly feedback on their child's progress via WhatsApp or SMS. The control schools will continue their usual activities and receive the intervention materials after the study ends.\n\nThe main outcome is the change in the proportion of children who are overweight or obese from the start of the study to 9 months later. Secondary outcomes include changes in BMI z-score, waist circumference, physical activity, eating habits, and parents' knowledge. A follow-up assessment at 12 months will check if any benefits last.\n\nRecruitment of schools and children began on January 8, 2026. This is the first cluster randomized trial of its kind in Pakistan. The results will help inform childhood obesity prevention policies in low- and middle-income countries.",[176],"Childhood Obesity Pevention",[178,179,180,181,182,183],"Obesity prevention","School-based intervention","Family-based intervention","Cluster randomized trial","Primary school children","Childhood obesity","2026-05-31",{"date":155,"type":43},{"date":187,"type":43},"2025-12-08",{"date":189,"type":21},"2026-12-08",{"name":49,"class":50},{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":199,"phases":4,"briefSummary":200,"conditions":201,"keywords":4,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":209,"locationsCount":51},"100597854","multimodal-deep-learning-for-predicting-treatment-response-to-neoadjuvant-chemoimmunotherapy-in-esophageal-cancer-100597854","NCT07063901","Multimodal Deep Learning for Predicting Treatment Response to Neoadjuvant Chemoimmunotherapy in Esophageal Cancer","Inclusion Criteria:\n\n1. Patients with histologically confirmed esophageal cancer based on biopsy results;\n2. Patients recommended for neoadjuvant chemoimmunotherapy following multidisciplinary team (MDT) discussion or evaluation by thoracic surgery specialists;\n3. Patients who received neoadjuvant chemoimmunotherapy;\n4. Patients with complete imaging data before and after neoadjuvant treatment.\n\nExclusion Criteria:\n\n1. Patients deemed eligible for surgery by the thoracic surgery team but who refused surgical treatment;\n2. Patients with missing or poor-quality CT images;\n3. Patients with concurrent malignancies other than esophageal cancer;\n4. Patients with incomplete clinical data.",{"count":198,"type":21},200,"OBSERVATIONAL","This observational study aims to investigate a clinical cohort of patients with locally advanced esophageal cancer undergoing neoadjuvant chemoimmunotherapy. By integrating multimodal clinical data-including demographic characteristics, medical history, imaging studies, pathological findings, and laboratory tests-and employing deep learning algorithms, the study seeks to develop predictive models for the early and accurate assessment of treatment response prior to surgery. Specifically, this study focuses on addressing the following key scientific questions:\n\n1. Can multimodal clinical data be used to construct an accurate model for predicting pathological complete response (pCR) following neoadjuvant therapy?\n2. Can deep learning models enable early identification of patients with suboptimal response to neoadjuvant therapy, defined as stable disease (SD) or progressive disease (PD), before surgery?",[202],"Esophagus Cancer","2026-05-11",{"date":205,"type":43},"2026-05-12",{"date":207,"type":43},"2025-06-01",{"date":184,"type":21},{"name":49,"class":50},{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":4,"eligibilityCriteria":216,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":217,"targetDuration":4,"studyType":199,"phases":4,"briefSummary":219,"conditions":220,"keywords":4,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":226,"leadSponsor":228,"locationsCount":51},"100598078","staging-strategies-and-their-association-with-prognosis-and-therapy-in-lung-cancer-with-cystic-airspaces-100598078","NCT07066813","Staging Strategies and Their Association With Prognosis and Therapy in Lung Cancer With Cystic Airspaces","T-Staging Strategies and Their Prognostic and Therapeutic Significance in Lung Cancer With Cystic Airspaces: A Retrospective Cohort Study","Inclusion Criteria:\n\n1. Histologically confirmed non-small cell lung cancer (NSCLC), as verified by biopsy or postoperative pathological examination;\n2. Patients who have undergone surgical lung resection;\n3. Patients with complete preoperative chest CT imaging data;\n4. Preoperative chest CT showing a well-defined gas-containing (air-filled) cystic component within the tumor.\n\nExclusion Criteria:\n\n1. History of pulmonary diseases that could produce cystic lung lesions (e.g., tuberculosis, pulmonary fungal infections, bullae, emphysema, Lymphangioleiomyomatosis \\[LAM\\], or Birt-Hogg-Dubé \\[BHD\\] syndrome);\n2. Systemic anti-tumor therapies, including chemotherapy, radiotherapy, or targeted therapies (such as monoclonal antibodies, small-molecule tyrosine kinase inhibitors, among others), were administered prior to enrollment;\n3. Patients with concurrent other malignancies;\n4. Patients with missing or poor-quality preoperative chest CT imaging data.",{"count":218,"type":21},500,"The goal of this observational study is to determine the most accurate tumor size measurement method for T-staging and prognostic assessment in lung cancer with cystic airspaces (LCCA). The main questions it aims to answer are:\n\n* What is the optimal T-staging approach for accurately classifying lung cancer with cystic airspaces （LCCA) and predicting patient outcomes?\n* How do imaging features of cystic lesions correlate with their pathological characteristics?\n* What is the relationship between imaging features of cystic airspace-associated lesions and patient prognosis?\n* Can optimizing the T-staging method improve clinical decision-making in patients with LCCA?",[221],"Lung Cancer Associated With Cystic Airspaces","2026-03-16",{"date":224,"type":43},"2026-03-18",{"date":207,"type":43},{"date":227,"type":21},"2026-07-01",{"name":49,"class":50},{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":4,"eligibilityCriteria":235,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":236,"targetDuration":4,"studyType":199,"phases":4,"briefSummary":238,"conditions":239,"keywords":4,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":242,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":51},"100569879","multi-omics-study-of-early-stage-lung-cancer-with-distinct-phenotypes-100569879","NCT06699979","Multi-omics Study of Early-stage Lung Cancer With Distinct Phenotypes","Comprehensive Multi-Omics Analysis of Early-Stage Lung Cancer Exhibiting Distinct Phenotypes","Cohort 1: Multi-omics study in early-stage synchronous multiple primary lung cancer\n\nInclusion criteria:\n\n1. Male or female patients:18-75 years old;\n2. ECOG score:0-1;\n3. Histopathologically confirmed TNM stage I-II NSCLC;\n4. Considered multiple or solitary primary lung cancer by clinical criteria (Martini-Melamed criteria and ACCP criteria);\n5. Good compliance, family members agree to cooperate to receive survival follow-up;\n6. Understand and voluntarily sign the informed consent.\n\nExclusion criteria:\n\n1. A history of previous or co-existing malignant tumors;\n2. Systemic anti-tumor therapies, including chemotherapy, radiotherapy, or targeted therapies (such as monoclonal antibodies, small-molecule tyrosine kinase inhibitors, among others), were administered prior to enrollment;\n3. Refusal to participate in the study.\n\nCohort 2: Multi-omics study of lung cancer associated with cystic airspaces\n\nInclusion criteria:\n\n1. Male or female patients:18-75 years old;\n2. ECOG score:0-1;\n3. Histopathologically confirmed TNM stage I-II NSCLC;\n4. CT findings show solitary or multiple nodules with cystic airspaces.\n\nExclusion criteria:\n\n1. A history of previous or co-existing malignant tumors;\n2. Systemic anti-tumor therapies, including chemotherapy, radiotherapy, or targeted therapies (such as monoclonal antibodies, small-molecule tyrosine kinase inhibitors, among others), were administered prior to enrollment;\n3. Refusal to participate in the study.",{"count":237,"type":21},300,"The goal of this observational study is to investigate the multi-omics characterization early-stage lung cancer exhibiting distinct phenotypes including lung cancer associated with cystic airspaces, multiple primary lung cancers, and so on. The main questions it aims to answer are:\n\n* What are the differences in pathogenesis of non-small cell lung cancer with different phenotypes explored by multi-omics?\n* Whether differential genes lead to potential prognostic models and therapeutic targets? Participants will be followed up after surgery to answer prognosis: whether they have recurred, and the time to recurrence.",[221,240,241],"Multiple Primary Lung Cancers","Non-Small Cell Lung Cancer",{"date":224,"type":43},{"date":244,"type":43},"2024-08-29",{"date":246,"type":21},"2027-12-31",{"name":49,"class":50},{"id":249,"slug":250,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":87,"enrollmentInfo":254,"targetDuration":4,"studyType":22,"phases":256,"briefSummary":257,"conditions":258,"keywords":260,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":51},"100627272","tis-for-improving-cognitive-impairment-associated-with-schizophrenia-100627272","NCT07446478","TIS for Improving Cognitive Impairment Associated With Schizophrenia","Efficacy and Safety of Time Interference Stimulation on Cognitive Impairment Associated With Schizophrenia",{"count":255,"type":21},10,[24],"This study aims to evaluate the efficacy and safety of TIS targeting the hippocampus in ameliorating cognitive impairment associated with schizophrenia (CIAS). Participants will receive TIS twice a day for 2 weeks. Their clinical data, including the baseline clinical symptom scale score, cognitive function, and MRI data, will be collected at baseline and at the end of the 2-week intervention.",[259],"Cognitive Impairment Associated With Schizophrenia (CIAS)",[96,97,98],"2026-03-12",{"date":263,"type":43},"2026-03-17",{"date":265,"type":21},"2026-03-15",{"date":267,"type":21},"2026-05-15",{"name":49,"class":50},{"id":270,"slug":271,"hasResults":11,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":4,"eligibilityCriteria":275,"healthyVolunteers":168,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":276,"targetDuration":4,"studyType":22,"phases":277,"briefSummary":278,"conditions":279,"keywords":282,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":51},"100627117","brain-network-mechanisms-of-cognitive-impairments-in-major-psychiatric-disorders-and-their-clinical-applications-100627117","NCT07444463","Brain Network Mechanisms of Cognitive Impairments in Major Psychiatric Disorders and Their Clinical Applications","Study on the Brain Network Mechanisms of Cognitive Impairments in Major Psychiatric Disorders and Their Application in Cognitive Assessment, Diagnosis, and Precision Treatment","Inclusion Criteria:\n\n* 1, For Patients (SZ, BD, MDD):\n\nDiagnosis of schizophrenia (SZ), bipolar disorder (BD), or major depressive disorder (MDD) according to standard diagnostic criteria\n\nFirst-episode drug-naïve patients or patients who have relapsed after discontinuing medication for more than one month\n\nAged 18-60 years\n\nCompletion of at least 6 years of formal education\n\n2, For Healthy Controls:\n\nAged 18-60 years\n\nCompletion of at least 6 years of formal education\n\nNo current or past psychiatric disorders\n\nNo first-degree relatives with psychiatric disorders\n\nNo history of treatment with psychotropic medications or physical therapy for psychiatric disorders\n\nExclusion Criteria:\n\n* Prior use of psychotropic medications or receipt of physical treatment for psychiatric disorders (for patient group)\n\nContraindications to MRI scanning\n\nHistory of brain injury\n\nHistory of substance abuse\n\nPresence of other neurological disorders\n\nPresence of severe medical or systemic physical illnesses.",{"count":143,"type":21},[24],"Previous and our studies have shown that cognitive impairments are core symptoms of three major psychiatric disorders-schizophrenia, bipolar disorder, and major depressive disorder, and are associated with underlying brain dysfunction. However, the specific brain networks involved in cognitive impairments (cognitive impairment brain networks) in these disorders, as well as whether their neuroimaging features can be applied to cognitive assessment, diagnosis, and precision treatment, remain unclear. This study aims to identify cognitive impairment brain networks using publicly available large-scale datasets and clinical research, and to explore whether the neuroimaging features of these networks can be utilized for cognitive assessment, diagnosis, and treatment response prediction. First, a \"sensitive cognitive assessment model for major psychiatric disorders\" will be established through meta-analysis based on sensitive scales. Second, cognitive impairment brain networks will be identified using publicly available large-scale datasets combined with the lesion network mapping method, and their validity will be examined by assessing their non-randomness, reproducibility, symptom specificity, and disease specificity. Third, cognitive assessment and diagnostic models will be developed based on neuroimaging features of these networks. Finally, a combination of cross-sectional and longitudinal study designs will be used in a clinical trial to validate the identified networks and models, and a treatment response prediction model will be established based on the neuroimaging features of cognitive impairment brain networks. This study will advance the understanding of the neurophysiological mechanisms underlying cognitive impairment in major psychiatric disorders, promote the application of neuroimaging in psychiatric diagnosis and treatment, and improve traditional diagnostic, therapeutic, and cognitive assessment approaches.",[148,280,281],"Bipolar Disorder","Major Depressive Disorder (MDD)",[96,97,283,284,285],"brain imaging","bipolar disorder","major depressive disorder","2026-03-02",{"date":288,"type":43},"2026-03-04",{"date":290,"type":21},"2027-01-01",{"date":292,"type":21},"2029-12-31",{"name":49,"class":50},{"id":295,"slug":296,"hasResults":11,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":4,"eligibilityCriteria":300,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":18,"enrollmentInfo":301,"targetDuration":4,"studyType":22,"phases":303,"briefSummary":304,"conditions":305,"keywords":306,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":309,"lastUpdatePostDateStruct":310,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":316,"locationsCount":51},"100565476","ntms-for-negative-symptom-in-schizophrenia-100565476","NCT06642675","nTMS for Negative Symptom in Schizophrenia","Effectiveness of Navigated Transcranial Magnetic Stimulation (nTMS) of Left Supramarginal Gyrus for Negative Symptoms : A Double-blind, Randomized Controlled Trial","Inclusion Criteria:\n\n* 1.Clinical diagnosis of schizophrenia according to ICD-11.\n* 2.Confirmation of the diagnosis of schizophrenia using the SCID-5-RV (DSM-5 Structured Clinical Interview for DSM-5 Disorders - Research Version).\n* 3.Score more than 4 points on either item of negative symptoms (N1-N7).\n* 4.Aged less than 60 years.\n\nExclusion Criteria:\n\n* 1.Clinical diagnosis or SCID-5-RV assessment confirming neurodevelopmental disorders, bipolar and related disorders, substance use disorders (excluding alcohol and tobacco).\n* 2.Presence of severe or acute physical illnesses, including traumatic brain injury, intracranial space-occupying or infectious diseases, acute cardiovascular diseases, acute respiratory system diseases, acute hematological disorders, etc.\n* 3.Presence of clearly defined genetic diseases, including tuberous sclerosis, multiple sclerosis, Kleefstra syndrome, 22q11.2 deletion syndrome, Prader-Willi syndrome, Klinefelter syndrome (47,XXY), etc.\n* 4.Contraindication for MRI examination or rTMS, such as metal implantation in the body, epilepsy, cochlear implants, etc.\n* 5.Severe risk of self-injury or suicide\n* 6.Other conditions where the researchers find unsuitable for the treatment",{"count":302,"type":21},40,[24],"This research aims to test the effectiveness of Navigated transcranial magnetic stimulation (nTMS) of left Supramarginal Gyrus for negative symptoms. In this double-blind, randomized controlled trial, patients will be assigned to active iTBS experimental group or sham iTBS group. Treatment will last for 10 days, and data will be collected at baseline, 1 day and 1 month after treatment.",[148],[96,307,308],"TMS","negative symptom","2025-12-01",{"date":311,"type":43},"2025-12-05",{"date":313,"type":43},"2024-11-22",{"date":315,"type":21},"2026-03",{"name":49,"class":50},{"id":318,"slug":319,"hasResults":11,"nctId":320,"briefTitle":321,"officialTitle":321,"acronym":322,"eligibilityCriteria":323,"healthyVolunteers":168,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":324,"targetDuration":325,"studyType":199,"phases":4,"briefSummary":326,"conditions":327,"keywords":330,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":51},"100567882","immunoinflammatory-state-detection-and-multimodal-brain-imaging-and-electrophysiologic-changes-in-schizophrenia-100567882","NCT06673966","Immunoinflammatory State Detection and Multimodal Brain Imaging and Electrophysiologic Changes in Schizophrenia","SZIM","Inclusion Criteria:\n\n1. Clinical diagnosis that meets ICD-11 criteria for schizophrenia.\n2. Confirmation of the diagnosis of schizophrenia using the SCID-5-RV.\n\nExclusion Criteria:\n\n1. Clinical diagnosis or SCID-5-RV assessment confirming neurodevelopmental disorders, bipolar and related disorders, substance use disorders (excluding alcohol and tobacco).\n2. Presence of severe or acute physical illnesses, including traumatic brain injury, intracranial space-occupying or infectious diseases, acute cardiovascular diseases, acute respiratory system diseases, acute hematological disorders, autoimmune disease, etc.\n3. Presence of clearly defined genetic diseases, including tuberous sclerosis, multiple sclerosis, Kleefstra syndrome, 22q11.2 deletion syndrome, Prader-Willi syndrome, Klinefelter syndrome (47, XXY), etc.",{"count":198,"type":21},"3 Months","Schizophrenia is a severe mental illness that seriously affects the health and functioning of patients. Previous studies have found immunoinflammatory abnormalities in the blood, cerebrospinal fluid, central nervous system, and neuroimaging of people with schizophrenia, along with therapeutic effects of anti-inflammatory drugs on schizophrenia. These evidences suggest a close relationship between schizophrenia and immunity and inflammation. Therefore, we consider that the state of immune inflammation is a potential subtype classification basis for schizophrenia, and hypothesize that immune classification based on peripheral-central multidimensional data is related to patient's response to medication and cognition.",[148,328,329],"Schizophrenia Spectrum and Other Psychotic Disorders","Mental Disorders",[148,331,332],"immunity","inflammation","2025-04-22",{"date":335,"type":43},"2025-04-24",{"date":337,"type":43},"2025-01-10",{"date":339,"type":21},"2028-12-31",{"name":49,"class":50},{"id":342,"slug":343,"hasResults":11,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":4,"eligibilityCriteria":347,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":348,"enrollmentInfo":349,"targetDuration":4,"studyType":22,"phases":351,"briefSummary":352,"conditions":353,"keywords":354,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":367},"100499423","itbs-for-increased-appetite-induced-by-antipsychotics-100499423","NCT05783063","iTBS for Increased Appetite Induced by Antipsychotics","Effects of Intermittent Theta Burst Stimulation (iTBS) on Increased Appetite Induced by Antipsychotics in Patients With Schizophrenia","Inclusion Criteria:\n\n1. Age between 18-40 years old;\n2. Meeting the diagnostic criteria for schizophrenia in DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition);\n3. BMI ≥ 25kg\u002Fm 2 or over 10% weight gain after taking antipsychotics in the last year;\n4. Not receiving TMS therapy in the past month;\n5. Using no more than two antipsychotic medications (including olanzapine, haloperidol, amisulpride, asenapine, risperidone, paliperidone, clozapine, quetiapine, iloperidone, chlorpromazine, sertindole, zotepine), not using antidepressants, mood stabilizers and other drugs, but allowing short-term use of benzodiazepines, benzhexol and propranolol;\n6. Signing written informed consents voluntarily.\n\nExclusion Criteria:\n\n1. Other severe mental illnesses, mental retardation, dementia and severe cognitive impairment according to diagnostic criteria of ICD-10 or DSM-5;\n2. Abnormal brain structure or function owing to any major physical disease, neurological disease, traumatic brain injury, etc.;\n3. Metallic implants, pacemakers, epilepsy history or other contraindications of TMS;\n4. Suicidal thoughts or behaviors;\n5. Alcohol or substance abuse;\n6. Pregnant or lactating women;\n7. Other contraindications of MRI;\n8. Receiving regular MECT, or weight-loss therapy in the latest month;\n9. Other abnormal examination results considered to be inappropriate for inclusion by researchers.","40 Years",{"count":350,"type":21},60,[24],"Antipsychotics are prone to cause metabolic side effects, including weight gain, hyperglycemia, insulin resistance, hyperlipidemia and so on, leading to a 2-3 times higher risk of death in patients with schizophrenia compared to healthy people. Conventional high-frequency rTMS have been used to treat people with obesity and showed certain effectiveness. However, studies involving schizophrenia patients and intermittent theta burst (iTBS) mode are rarely seen. The goal of this clinical trial is to evaluate the efficacy and safety of iTBS on ameliorating increased appetite induced by antipsychotics in people with schizophrenia.",[148],[148,355,356,357,358],"appetite","weight","antipsychotics","iTBS","2025-03-22",{"date":361,"type":43},"2025-03-26",{"date":363,"type":43},"2023-08-01",{"date":365,"type":21},"2026-08-01",{"name":49,"class":50},2,{"id":369,"slug":370,"hasResults":11,"nctId":371,"briefTitle":372,"officialTitle":372,"acronym":373,"eligibilityCriteria":374,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":59,"enrollmentInfo":375,"targetDuration":4,"studyType":22,"phases":377,"briefSummary":379,"conditions":380,"keywords":381,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":4},"100573683","phase-4-a-randomized-double-blind-placebo-controlled-multicenter-clinical-study-on-the-treatment-of-depression-with-jieyu-chufan-capsules-100573683","NCT06749470","A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study on the Treatment of Depression with Jieyu Chufan Capsules","JOYS","Inclusion criteria:\n\n1. Aged 18-65 years (inclusive);\n2. With first-episode or relapsed depression that meets the DSM-5 diagnostic criteria;\n3. With a Hamilton's Depression Scale (HAMD-17) score of ≥18 at enrollment;\n4. Receiving no antidepressants within 2 weeks (fluoxetine within 6 weeks) prior to enrollment;\n5. Willing to sign the informed consent form (ICF).\n\nExclusion criteria:\n\n1. Meeting the DSM-5 diagnostic criteria for mental disorders other than depression (e.g., patients with schizophrenia spectrum and other psychiatric disorders, bipolar and related disorders, compulsive and related disorders, etc.);\n2. With refractory depression (no response to adequate treatment with 2 or more antidepressants) as determined by the investigator or previously diagnosed;\n3. At a significant risk of suicide (HAMD-17 Item 3 (suicide) score ≥3) as judged by the investigator, or with a history of suicide attempts in the last year;\n4. Receiving non-drug therapies, such as electric convulsive therapy (ECT), repetitive transcranial magnetic stimulation (rTMS), and systematic psychotherapy 10 or more times in the last 6 months;\n5. With other serious chronic diseases such as severe thyroid disease, Parkinson's disease, tumor, epilepsy, and severe rheumatism;\n6. With clinically significant abnormalities in 12-lead ECG that may affect the safety of the subject, including but not limited to acute myocardial ischemia, myocardial infarction, severe arrhythmia, or significantly prolonged QTc (QTc \\>450 ms in men and \\>470 ms in women);\n7. With severe hepatic and renal insufficiency, i.e., aspartate transaminase (AST) ≥1.5 × upper limit of normal (ULN) or alanine aminotransferase (ALT) ≥1.5 × ULN, and serum creatinine (Scr) ≥1.5× ULN;\n8. Allergic to the investigational drug or its ingredients;\n9. In lactation, of childbearing potential, or planning to be pregnant;\n10. With alcohol and drug dependence;\n11. Participating in another clinical study within 1 month prior to enrollment or for the time being.\n12. Not suitable for participation in this study due to potential risks or other factors as considered by the investigator.",{"count":376,"type":21},480,[378],"PHASE4","To evaluate the efficacy of Jieyu Chufan Capsules, with placebo as the control, in combination with SSRIs in patients with moderate and severe depression.\n\nTo observe the safety of Jieyu Chufan Capsules and its effects in improving the side effects of SSRIs.",[281],[382,383,281],"Jieyu Chufan Capsules","TCM","2024-12-23",{"date":386,"type":43},"2024-12-27",{"date":388,"type":21},"2024-12-22",{"date":390,"type":21},"2026-12-31",{"name":49,"class":50},{"id":393,"slug":394,"hasResults":11,"nctId":395,"briefTitle":396,"officialTitle":397,"acronym":4,"eligibilityCriteria":398,"healthyVolunteers":11,"sex":16,"minAge":399,"maxAge":17,"enrollmentInfo":400,"targetDuration":4,"studyType":22,"phases":401,"briefSummary":402,"conditions":403,"keywords":405,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":411,"lastUpdatePostDateStruct":412,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":418,"locationsCount":51},"100571689","high-definition-transcranial-direct-current-stimulation-of-right-inferior-frontal-gyrus-to-improve-social-impairments-in-children-with-autism-100571689","NCT06723522","High Definition Transcranial Direct Current Stimulation of Right Inferior Frontal Gyrus to Improve Social Impairments in Children with Autism","The Efficacy and Brain Mechanism of High Definition Transcranial Direct Current Stimulation of Right Inferior Frontal Gyrus to Improve Social Impairments in Children with Autism Spectrum Disorder: a Randomized, Double-blind, Controlled Study","Inclusion Criteria:\n\n* had to be 3-18 years old; be diagnosed with ASD (according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and Autism Diagnostic Interview - Revised (ADI-R).\n\nExclusion Criteria:\n\n* with other comorbid neuropsychiatric conditions (i.e., schizophrenia spectrum disorders and mood disorders) or neurological disorders (i.e., head trauma and epilepsy).","3 Years",{"count":350,"type":21},[24],"The goal of this clinical trial is to learn if high definition transcranial direct current stimulation (HD-tDCS) of right inferior frontal gyrus works to improve social impairments in children with autism spectrum disorder (ASD). It will also learn about the underlying brain mechanism. The main questions it aims to answer are:\n\n* Does HD-tDCS of right inferior frontal gyrus improve social impairments in children with ASD?\n* What are the underlying brain mechanisms by which the HD-tDCS of right inferior frontal gyrus improves social impairments in children with ASD? Researchers will compare participants received active HD-tDCS to controls received sham HD-tDCS (performed to mimic the sensation induced by real HD-tDCS before and after the stimulation) to see if HD-tDCS of right inferior frontal gyrus improves social impairments in children with ASD.\n\nParticipants will:\n\n* Receive a dose of 2 mA HD-tDCS of right inferior frontal gyrus lasting for 10 days.\n* Receive social functioning assessment, functional near-infrared spectroscopy and electroencephalography measurement before and after stimulation\n* Visit the clinic once every 2 weeks for checkups and tests, a total of 2 times.",[404],"Autism Spectrum Disorder (ASD)",[406,407,408,409,410],"autism","tDCS","social","fNIRS","RCT","2024-12-17",{"date":413,"type":43},"2024-12-19",{"date":415,"type":43},"2024-08-30",{"date":417,"type":21},"2026-07-31",{"name":49,"class":50},{"id":420,"slug":421,"hasResults":11,"nctId":422,"briefTitle":423,"officialTitle":423,"acronym":4,"eligibilityCriteria":424,"healthyVolunteers":168,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":425,"targetDuration":427,"studyType":199,"phases":4,"briefSummary":428,"conditions":429,"keywords":430,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":433,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":438,"locationsCount":439},"100525604","establishing-a-clinical-database-and-biobank-for-schizophreniaa-cohort-study-100525604","NCT06123897","Establishing a Clinical Database and Biobank for Schizophrenia：A Cohort Study","Inclusion Criteria:\n\n* 1.Clinical diagnosis of schizophrenia according to ICD-11.\n* 2.Confirmation of the diagnosis of schizophrenia using the SCID-5-RV (DSM-5 Structured Clinical Interview for DSM-5 Disorders - Research Version).\n\nExclusion criteria:\n\n* 1.Clinical diagnosis or SCID-5-RV assessment confirming neurodevelopmental disorders, bipolar and related disorders, substance use disorders (excluding alcohol and tobacco).\n* 2.Presence of severe or acute physical illnesses, including traumatic brain injury, intracranial space-occupying or infectious diseases, acute cardiovascular diseases, acute respiratory system diseases, acute hematological disorders, etc.\n* 3.Presence of clearly defined genetic diseases, including tuberous sclerosis, multiple sclerosis, Kleefstra syndrome, 22q11.2 deletion syndrome, Prader-Willi syndrome, Klinefelter syndrome (47,XXY), etc.",{"count":426,"type":21},2000,"1 Year","This is a multicenter study conducted in collaboration with Central South University, The First Affiliated Hospital of Zhengzhou University, Nanjing Brain Hospital of Nanjing Medical University, and Anhui Mental Health Center. The project intends to employ standardized diagnostic criteria and clinical assessment procedures to establish a comprehensive cohort of patients with schizophrenia, encompassing all age groups and disease stages, with follow-up periods exceeding one year. The goal is to create an internationally high-standard clinical cohort database and biobank for schizophrenia. Through a multidimensional assessment framework, the project aims to further investigate the etiology of schizophrenia, patterns of disease progression, and clinical outcomes. By periodically capturing dynamic information on risk and preventive factors, the project aims to achieve early diagnosis, early treatment, and improved prognosis for patients. Additionally, it seeks to explore potential biomarkers within the realm of precision medicine that can predict treatment efficacy, providing viable tools for precision healthcare and clinical decision-making in the field of schizophrenia.",[148],[431],"Schizophrenia, Cohort Study","2024-11-21",{"date":434,"type":43},"2024-11-25",{"date":436,"type":43},"2024-01-01",{"date":339,"type":21},{"name":49,"class":50},4,{"id":441,"slug":442,"hasResults":11,"nctId":443,"briefTitle":444,"officialTitle":445,"acronym":4,"eligibilityCriteria":446,"healthyVolunteers":168,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":447,"targetDuration":4,"studyType":22,"phases":449,"briefSummary":450,"conditions":451,"keywords":453,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":457,"startDateStruct":459,"completionDateStruct":461,"leadSponsor":463,"locationsCount":51},"100549050","investigating-the-insulin-resistance-in-individuals-with-type-2-diabetes-100549050","NCT06428968","Investigating the Insulin Resistance in Individuals With Type 2 Diabetes","Investigating the Central and Peripheral Insulin Resistance in Individuals With Type 2 Diabetes","Inclusion Criteria:\n\n* Meeting the diagnostic criteria for Type 2 diabetes: typical symptoms of diabetes plus random blood glucose level of ≥11.1 mmol\u002Fl, or fasting blood glucose level of ≥7.0 mmol\u002Fl, or 2-hour post-OGTT (Oral Glucose Tolerance Test) blood glucose level of ≥11.1 mmol\u002Fl, or HbA1c level of ≥6.5%; for those without typical symptoms of diabetes, re-examination on a different day is required for confirmation.\n\nExclusion Criteria:\n\n* Having history of substance dependence or abuse or whose symptoms are caused by diagnosable mental disorders;\n* Having history of traumatic brain injury, seizures or other known neurological or organic diseases of the central nervous system;\n* Having current suicidal or homicidal thoughts or any safety concern by research staff that cannot be manage in an inpatient setting;\n* Taking drugs that could affect cognitive function.\n* The routine blood tests showing significant abnormal renal, liver function or other somatic disease.\n* Pregnant or lactating women.",{"count":448,"type":21},30,[24],"Numerous studies have provided evidence of a correlation between Type 2 Diabetes Mellitus (T2DM) and cognitive dysfunction, specifically in the realms of complex attention, information processing, and executive function. These impairments have been observed in middle-aged and elderly individuals with T2DM, with longer diabetes duration, suboptimal glycemic control, and the presence of diabetic complications being contributing factors. Recent research in young adults and adolescents diagnosed with T2DM has revealed cognitive and brain structural alterations in this growing demographic, suggesting that early disease mechanisms, rather than solely vascular and age-related neurodegeneration, contribute to pathogenesis. However, there remains uncertainty regarding the interplay between central and peripheral insulin resistance and its impact on cognitive dysfunction in individuals with T2DM. This study aims to investigate central insulin resistance in T2DM, elucidating its association with peripheral insulin resistance and the effects on cognitive impairments.",[452],"Type 2 Diabetes",[454,455],"Insulin resistance","Cognitive impairments","2024-09-09",{"date":458,"type":43},"2024-09-19",{"date":460,"type":43},"2024-09-06",{"date":462,"type":21},"2025-06-30",{"name":49,"class":50},{"id":465,"slug":466,"hasResults":11,"nctId":467,"briefTitle":468,"officialTitle":469,"acronym":4,"eligibilityCriteria":470,"healthyVolunteers":11,"sex":16,"minAge":170,"maxAge":17,"enrollmentInfo":471,"targetDuration":4,"studyType":22,"phases":472,"briefSummary":473,"conditions":474,"keywords":478,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":481,"lastUpdatePostDateStruct":482,"startDateStruct":484,"completionDateStruct":486,"leadSponsor":488,"locationsCount":367},"100532230","aitbs-for-nssi-and-suicide-in-adolescent-depression-100532230","NCT06210100","aiTBS for NSSI and Suicide in Adolescent Depression","Efficacy and Safety of Accelerated Intermittent Theta Burst Stimulation on Non-suicidal Self-injury and Suicide Behaviors in Adolescents With Unipolar or Bipolar Depression","Inclusion Criteria:\n\n1. Meet the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders 5th Edition) diagnostic criteria for major depressive disorder.\n2. Patients aged 12-18 years with at least one guardian to monitor them for 3 months\n3. HAMD-17 Total score ≥18\n4. Hospitalized patients who had two or more non-suicidal self-injury behaviors meeting the DSM-5 diagnostic criteria in the week before admission (NSSI behavior of more than 5 days in the past year, and a baseline DSHI score ≥2 )\n5. Obtain informed consent from patients and guardians\n\nExclusion Criteria:\n\n1. Substance abusers such as psychoactive drugs or alcohol.\n2. Severe physical disability and unable to complete follow-up.\n3. Comorbid other major mental illnesses that meet the DSM-5 criteria, such as bipolar disorder, schizophrenia, mental retardation, dementia, severe cognitive impairment, attention deficit hyperactivity disorder, etc.\n4. Suffering from any severe physical disease, neurological disease, traumatic brain injury, etc, that affects the structure or function of the brain in the lifetime.\n5. Unable to read, understand and complete the assessment or to cooperate with the investigators.\n6. Any implants covering a pacemaker, metallic or magnetic objects in the body, or other conditions not suitable for rTMS.\n7. A history or family history of epilepsy and other contraindications to TMS.\n8. Daily use of benzodiazepines (more than 2mg\u002Fd), theophylline, stimulants such as methylphenidate, anticonvulsants, etc.\n9. Those who have received systematic psychotherapy (interpersonal relationship therapy, dynamic therapy, cognitive behavioral therapy) or TMS within 3 months before baseline.\n10. Other examination abnormalities considered to be inappropriate by investigators.",{"count":350,"type":21},[24],"Repetitive transcranial magnetic stimulation (rTMS) has been successfully used to help patients with treatment resistant depression. However, its role in alleviating self injuries with and without suicidal ideation remained uncertain. This trial will compare the effectiveness of active accelerated intermittent theta burst stimulation (aiTBS) rTMS to a placebo control on non-suicidal self injury (NSSI) and suicidal attempts in patients with major depressive disorder.",[475,476,477],"Non Suicidal Self Injury","Suicidal Ideation","Suicide and Self-harm",[479,480,307],"NSSI","MDD","2024-08-15",{"date":483,"type":43},"2024-08-16",{"date":485,"type":43},"2024-01-18",{"date":487,"type":21},"2025-02-01",{"name":49,"class":50},{"id":490,"slug":491,"hasResults":11,"nctId":492,"briefTitle":493,"officialTitle":494,"acronym":4,"eligibilityCriteria":495,"healthyVolunteers":11,"sex":16,"minAge":496,"maxAge":497,"enrollmentInfo":498,"targetDuration":4,"studyType":199,"phases":4,"briefSummary":499,"conditions":500,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":502,"lastUpdatePostDateStruct":503,"startDateStruct":505,"completionDateStruct":507,"leadSponsor":509,"locationsCount":4},"100555395","exploring-sarcopenia-in-parkinsons-disease-patients-by-combining-serum-biomarker-levels-100555395","NCT06511531","Exploring Sarcopenia in Parkinson's Disease Patients by Combining Serum Biomarker Levels","Clinical Features and Possible Mechanisms in Patients With Sarcopenia in Parkinson's Disease","Inclusion Criteria:\n\nDiagnosed as either ''definite'' or ''probable'' PD based on Chinese diagnostic criteria of Parkinson\\'s disease (2016 version)\n\nExclusion Criteria:\n\nParkinson\\'s syndrome or Parkinsonian superimposed syndrome due to encephalitis, cerebrovascular disease, poisoning, trauma, drugs or other factors","30 Years","80 Years",{"count":198,"type":21},"Parkinson\\'s Disease (PD) and sarcopenia are prevalent age-related syndromes, often occurring simultaneously within individuals. Sarcopenia is notably common among PD patients, with severe cases affecting approximately one in every five individuals with PD. Moreover, sarcopenia is closely linked to the accelerated progression of PD, diminished quality of life, heightened mortality risk, and increased susceptibility to falls and fractures. Therefore, early detection of sarcopenia assumes particular significance as it offers an opportunity for interventions aimed at mitigating or delaying muscle degeneration, potentially influencing PD outcomes. This review will delve into the relationship between sarcopenia and PD, methods for screening and testing sarcopenia, and potential avenues for further research and the development of strategies for risk reduction and treatment",[501],"Parkinson Disease","2024-07-15",{"date":504,"type":43},"2024-07-22",{"date":506,"type":21},"2024-08-01",{"date":508,"type":21},"2024-09-01",{"name":49,"class":50},{"id":511,"slug":512,"hasResults":11,"nctId":513,"briefTitle":514,"officialTitle":514,"acronym":4,"eligibilityCriteria":515,"healthyVolunteers":11,"sex":16,"minAge":516,"maxAge":4,"enrollmentInfo":517,"targetDuration":4,"studyType":199,"phases":4,"briefSummary":518,"conditions":519,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":521,"lastUpdatePostDateStruct":522,"startDateStruct":524,"completionDateStruct":526,"leadSponsor":528,"locationsCount":4},"100551180","clinical-features-and-prognostic-markers-in-adult-patients-with-ae-requiring-icu-treatment-100551180","NCT06456736","Clinical Features and Prognostic Markers in Adult Patients With AE Requiring ICU Treatment","Inclusion Criteria:\n\n* Diagnosed as either ''definite'' or ''probable'' AE based on Chinese guidelines for diagnosis and treatment of AE (version 2022)\n* Age ≥ 15 years\n* Admission to an adult ICU during the course of the disease\n\nExclusion Criteria:\n\n* Missing data on primary outcome\n* ICU length of stay of 24 hours or less.","15 Years",{"count":198,"type":21},"Autoimmune encephalitis (AE) is a potentially life-threatening inflammation of the central nervous system (CNS) and constitutes 20%-30% of encephalitis cases in adults AE often leads to subacute, severe, and debilitating encephalitis necessitating long-term management in a neurologic intensive care unit (ICU). This study aims to explore the predictive factors for poor clinical outcomes by analyzing the clinical characteristics and prognosis of adult patients with critical AE requiring ICU admission. Prospective observational single center study in neurologic ICU, the second Xiangya hospital, Central South University. All patients admitted to the ICU for probable or confirmed AE (2022 Chinese guidelines for diagnosis and treatment of AE) will be included. Factors associated with a poor prognosis will be identified by multivariate analysis using a logistic regression.",[520],"Autoimmune Encephalitis","2024-06-12",{"date":523,"type":43},"2024-06-13",{"date":525,"type":21},"2024-06",{"date":527,"type":21},"2024-08",{"name":49,"class":50},{"id":530,"slug":531,"hasResults":11,"nctId":532,"briefTitle":533,"officialTitle":534,"acronym":4,"eligibilityCriteria":535,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":536,"targetDuration":4,"studyType":22,"phases":538,"briefSummary":539,"conditions":540,"keywords":542,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":546,"lastUpdatePostDateStruct":547,"startDateStruct":549,"completionDateStruct":551,"leadSponsor":553,"locationsCount":51},"100528522","phase-4-clinical-study-of-individualized-vancomycin-dosing-based-on-population-pk-model-100528522","NCT06161870","Clinical Study of Individualized Vancomycin Dosing Based on Population PK Model","Clinical Study of Individualized Vancomycin Dosing Based on Population Pharmacokinetic Model for Severe Infections","Inclusion Criteria:\n\n1. Admission to neurological intensive care unit (NICU).\n2. Age ≥18 years old. Participants will be eligible if they meet both of these criteria.\n\nExclusion Criteria:\n\n1. Evidence of absolute renal impairment, which included Serum creatinine (SCR) ≥133 μmol\u002FL at admission, development of acute kidney injury (AKI) after admission, need for renal replacement therapy during hospitalization, renal related tests suggestive of renal disease, and previous history of renal replacement therapy or chronic kidney disease.\n2. Pregnant participants.\n3. Primary diagnosis is non-neurological disease.\n4. The height or weight of participants is not recorded in the medical record system.\n5. The frequency of SCR monitoring was less than 3 times. Participants who meet any of these criteria will be excluded.",{"count":537,"type":21},112,[378],"The goal of this clinical trial is to compare the clinical efficacy of individualized dosing based on the population pharmacokinetics (PK) model and empirical dosing of vancomycin in participants with severe infections.\n\nIt aims to answer whether individual vancomycin dosing based on population PK model is superior to empirical dosing in terms of clinical efficacy and safety.\n\nParticipants will be randomly divided into experimental group and control group. The experimental group will be guided by the population PK model for individual dosing, and the control group will be given empirical dosing. Demographic data, clinical characteristics of participants, and their trough concentrations (Cmin) and peak concentrations (Cmax) of vancomycin will be collected. Area under the concentration curve (AUC24) of participants will be calculated using the first-order PK equation.\n\nResearchers will compare experimental group and control group to see if individual vancomycin dosing based on population PK model is superior to empirical dosing in terms of clinical efficacy and safety.",[541],"Severe Infection",[543,544,545],"vancomycin","population pharmacokinetic model","severe infection","2023-11-30",{"date":548,"type":43},"2023-12-08",{"date":550,"type":43},"2021-01-01",{"date":552,"type":21},"2024-12",{"name":49,"class":50},{"id":555,"slug":556,"hasResults":11,"nctId":557,"briefTitle":558,"officialTitle":559,"acronym":4,"eligibilityCriteria":560,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":561,"targetDuration":325,"studyType":199,"phases":4,"briefSummary":562,"conditions":563,"keywords":565,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":569,"lastUpdatePostDateStruct":570,"startDateStruct":572,"completionDateStruct":574,"leadSponsor":576,"locationsCount":51},"100469759","a-correlation-study-of-cognitive-function-in-patients-with-depression-100469759","NCT05396989","A Correlation Study of Cognitive Function in Patients With Depression","Near-infrared, Eye Movement and Depressive Symptoms in Patients With Depression Correlation Study of Cognitive Function: a Prospective Observational Cohort Study","Inclusion Criteria:\n\n1. Meets the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, 5th Edition) diagnostic criteria for depressive disorders\n2. Age 18-60 years, gender aside, at least 1 guardian to monitor the patient for 2 months\n3. Obtain informed consent from patients and guardians, sign informed consent forms, and be able to comply with planned visits, laboratory tests, and other research procedures\n4. It is expected that there will be no problems such as relocation of residence, inconvenience of transportation, and difficulty in obtaining medical treatment throughout the study process\n5. There is sufficient audiovisual level to complete the necessary examinations for the study\n\nExclusion Criteria:\n\n1. Presence of any other medical disorder affecting reproductive endocrine function; Abusers of psychoactive substances or substances such as alcohol\n2. People with severe physical disabilities who are unable to complete follow-up\n3. Have been diagnosed or have had other severe psychiatric disorders that meet the diagnostic criteria for DSM-5, mental retardation, dementia, severe cognitive dysfunction, etc\n4. Previously or currently suffering from any major physical disease, neurological disorder, brain trauma, etc. that affect the structure or function of the brain\n5. Suicidal or uncooperative\n6. Pregnant or lactating women\n7. There is significant anxiety, HAMA ≥ 21 points",{"count":198,"type":21},"Many studies have shown that patients with depression had weak brain region connections and low levels of activation of the prefrontal lobe when brain activity was active and that patients with depression have a negative attentional bias, and the patient's abnormal attentional allocation may stem from a loss of attention avoidance of negative cues and a loss of attention preference for positive cues. Here use the near-infrared, eye movement to evaluate the cognitive function in patients with depression. The purpose of the study is to explore the correlation between depressed symptom and cognition function among the depression patients and the difference between first-onset of depressed patients and those is recurrent.",[564],"Depression",[564,566,567,568],"cognition function","Near-infrared","Eye movement","2023-06-30",{"date":571,"type":43},"2023-07-03",{"date":573,"type":21},"2024-05-06",{"date":575,"type":21},"2028-05-28",{"name":49,"class":50},""]